Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 30% pre-market. This is why it happened.

CKPT Stock Price: Over 30% Increase Pre-Market Explanation

NEW YORK, May 12, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the completion of enrollment for the metastatic cutaneous squamous cell carcinoma (“cSCC”) cohort in its registration-enabling clinical trial of anti-PD-L1 antibody, cosibelimab.

Checkpoint Therapeutics Announces Completion of Enrollment in the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Peabody Energy

Auris Medical Hld

Ebang International Holdings

Meme penny stocks are a budding sector; have you heard of these 4? The post 4 Meme Penny Stocks To Watch As DogeCoin Rises appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Meme Penny Stocks To Watch As DogeCoin Rises

NEW YORK, May 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the first quarter ended March 31, 2021, and recent corporate highlights.

Checkpoint Therapeutics Reports First Quarter 2021 Financial Results and Recent Corporate Highlights

Agile Therapeutics

Aqua Metals

Catabasis Pharmaceuticals

Hepion Pharmaceuticals Inc

InflaRx

Limelight Networks

Investors in penny stocks know the prices of many have crashed. But these seven stocks may have room to run higher.

7 Penny Stocks That May Have Room to Run Higher

NEW YORK, March 09, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2020 and recent corporate highlights.

Checkpoint Therapeutics Reports Full-Year 2020 Financial Results and Recent Corporate Highlights

Members include preeminent clinical and scientific thought leaders in oncology Members include preeminent clinical and scientific thought leaders in oncology

Checkpoint Therapeutics Announces Formation of Scientific Advisory Board

Shares of Checkpoint Therapeutics Inc (NASDAQ: CKPT) have received a price target of $16 by Cantor Fitzgerald. These are the details.

CKPT Stock Price: $16 Target By Cantor Fitzgerald

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.

Checkpoint Therapeutics to Participate in Three January 2021 Virtual Investor Conferences

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out what the billionaire investors and hedge funds think of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT).

Is Checkpoint Therapeutics, Inc. (CKPT) A Good Stock To Buy?

NEW YORK, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim results from the ongoing global, open-label, multicohort Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including a cohort of patients with previously untreated high PD-L1 expressing advanced non-small cell lung cancer (“NSCLC”). The updated interim results are being presented in a poster presentation at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting being held virtually from November 9-14, 2020.  

Checkpoint Therapeutics Announces Presentation of Updated Cosibelimab Lung Cancer Results at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting

NEW YORK, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the third quarter ended September 30, 2020, and recent corporate highlights.

Checkpoint Therapeutics Reports Third Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, Sept.  17, 2020  (GLOBE NEWSWIRE) --  Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 7,142,857 shares of common stock of the Company, at a price to the public of $2.80 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about September 22, 2020, subject to satisfaction of customary closing conditions.

Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering

NEW YORK, Sept.  17, 2020  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced updated interim results from the ongoing global, open-label, multicohort, Phase 1 clinical trial of its anti-PD-L1 antibody, cosibelimab, in patients with advanced cancers, including the registration-enabling cohort of patients with metastatic cutaneous squamous cell carcinoma (“mCSCC”). Cosibelimab demonstrated a 51.4% objective response rate (“ORR”) and 13.5% complete response rate, which is nearly double the complete response rate observed at the time of previous analysis. This trial, upon successfully meeting the pre-defined endpoints, is intended to support marketing approval application submissions for cosibelimab worldwide. The interim results were presented in an e-poster at the European Society for Medical Oncology (“ESMO”) Virtual Congress 2020. 

Checkpoint Therapeutics Announces Positive Interim Results from Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

Following up on a prior interview on the status of its leading immunotherapy product candidate, cosibelimab, Benzinga spoke with Checkpoint Therapeutics President and CEO James Oliviero about the progress of the pivotal trial in CSCC and the evolving regulatory landscape in which it’s being conducted.

Checkpoint Therapeutics To Release Significant Drug Data At This Week's ESMO Congress

NEW YORK, Aug.  17, 2020  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James F. Oliviero, President and Chief Executive Officer, will present a company overview and participate in a panel discussion at the Fortress Biotech Virtual Summit hosted by Mayank Mamtani, of B. Riley FBR, Inc., on Wednesday, August 19, 2020 at 1:50 p.m. ET. A registration link and webcast information can be found below.

Checkpoint Therapeutics to Present at Virtual Corporate Access Summit Hosted by B. Riley FBR on Wednesday, August 19, 2020

NEW YORK, Aug.  05, 2020  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced financial results for the second quarter ended June 30, 2020, and recent corporate highlights.

Checkpoint Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights

NEW YORK, July  27, 2020  (GLOBE NEWSWIRE) --  Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that an abstract highlighting updated interim safety and efficacy data from the ongoing registration-enabling clinical trial of cosibelimab in patients with metastatic cutaneous squamous cell carcinoma (“mCSCC”) has been accepted for e-poster presentation at the European Society for Medical Oncology (“ESMO”) Virtual Congress 2020, to be held September 19-21, 2020.

Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020

- U.S. patent protection through at least May 2038  - Registration-enabling study of cosibelimab in cutaneous squamous cell carcinoma over one-third enrolled

Checkpoint Therapeutics Announces Issuance of U.S. Composition of Matter Patent for Anti-PD-L1 Antibody Cosibelimab

CKPT expects to submitt a BLA for cosibelimab in 2021.

Checkpoint Therapeutics: Beat The System

NEW YORK, Jan.  13, 2020  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that feedback from the U.S. Food and Drug Administration (“FDA”) has confirmed the company’s plan to submit cosibelimab for full approval as a treatment for patients with metastatic cutaneous squamous cell carcinoma (“CSCC”) based on efficacy and safety data from the ongoing open-label, multicenter, Phase 1 clinical trial, Study CK-301-101 (NCT03212404). This registration-enabling clinical trial is currently enrolling a cohort of patients with metastatic CSCC, with a target enrollment of approximately 75 to 100 patients and a primary efficacy endpoint of confirmed objective response rate (“ORR”) assessed by independent central review.

Checkpoint Therapeutics Announces Confirmation of Registration Path for Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

NEW YORK, Nov.  20, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the pricing of its previously announced underwritten public offering. Checkpoint is offering 13,400,000 shares of its common stock, par value $0.0001 per share, at a price to the public of $1.27 per share. In connection with the offering, Checkpoint has also granted the underwriters a 45-day option to purchase up to an additional 2,010,000 shares of common stock offered in the public offering, at the same public offering price per share, less underwriting discounts and commissions.

Checkpoint Therapeutics Announces Pricing of Public Offering of Common Stock

NEW YORK, Nov.  19, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Checkpoint expects to grant the underwriters a 45‐day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering. All of the shares of common stock are being offered by Checkpoint. Checkpoint intends to use the net proceeds from the offering primarily to support the continued development of cosibelimab, including an ongoing Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts intended to support one or more Biologics License Application submissions, and for general corporate purposes. The final terms of the offering will depend on market and other conditions at the time of pricing, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Checkpoint Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Nov.  08, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (Checkpoint) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that new pharmacokinetic and target occupancy modeling data for cosibelimab (formerly referred to as CK-301) are being presented today at the Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting, taking place in National Harbor, MD.

Checkpoint Therapeutics Announces Presentation of Anti-PD-L1 Cosibelimab Data at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting

NEW YORK, Sept.  30, 2019  (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that positive interim results for cosibelimab, a potentially differentiated high affinity anti-PD-L1 antibody with functional Fc domain, were presented on Saturday, September 28th, at the European Society for Medical Oncology (ESMO) Congress 2019 in Barcelona, Spain. The poster presentation provided updated interim efficacy and safety results from Checkpoint’s ongoing multicenter Phase 1 clinical trial, including expansion cohorts in cutaneous squamous cell carcinoma (“CSCC”) and non-small cell lung cancer (“NSCLC”). Checkpoint continues to enroll CSCC patients to support an initial Biologics License Application (“BLA”) submission for cosibelimab based on this ongoing clinical trial.

Checkpoint Therapeutics Announces Presentation of Positive Interim Clinical Results for Anti-PD-L1 Cosibelimab at the European Society for Medical Oncology (ESMO) Congress 2019

News for Checkpoint Therapeutics Stock (CKPT)